Navinci will attend AACR on April 14-19th in Orlando, US. We will showcase our latest product designs and tell you what is new in protein-protein interaction technology. You can find us in the exhibition hall (booth 1771) and at the scientific sessions with four poster presentations.
We would love to meet you, please book a meeting with us here
Naveni TriFlex Cell: An emerging method for simultaneous detection of free proteins and their interactions
Session: PO.CH02.02 – Proteomics and Biomarker Discovery
Date and Time: Monday Apr 17, 2023 9:00 AM – 12:30 PM
Poster #5 in section 31
Read abstract #2021
Automation of proximity ligation immunoassay for interaction between PDL1 and PD1 detection in the tumor microenvironment using microfluidic based system
Session: PO.CL01.04 – Biomarkers of Therapeutic Benefit 4
Date and Time: Tuesday Apr 18, 2023 9:00 AM – 12:30 PM
Poster #11 in section 37
Read abstract #4336
In situ detection of various activated immune checkpoints via next-generation proximity ligation assays in tumor tissue
Session: PO.IM01.05 – Immune Checkpoints
Date and Time: Wednesday Apr 19, 2023 9:00 AM – 12:30 PM
Poster #16 in section 23
Read abstract #6372
Powerful background reduction in fluorescent tissue stains with an improved proximity-based technology for detection of protein-protein interactions
Session: PO.CL01.13 – Spatial Proteomics and Transcriptomics 2
Date and Time: Wednesday Apr 19, 2023 9:00 AM – 12:30 PM
Poster #12 in section 43
Read abstract #6772
Learn how to maximize information from every analysis by localizing and quantifying proteins, their interactions, and modifications in situ at a molecular level. In situ methods are commonly used in the cancer research field, and studies of protein-protein interactions (PPI) and protein translational modifications (PTM) are essential for:
All our products are based on our proprietary Naveni Proximity Ligation technology with dual antibody recognition giving you more specific and sensitive detection of your target of interest. Click here to read about the technology.
To our flexible products – to use with your primary antibodies
To our specific products – for the precise detection of PD1/PD-L1 interaction, and phosphorylated proteins PD1, Met, VEGFR2, EGFR, HER2, and PDGFR-beta.
We have some exciting developments to present at the AACR conference! We have continued the development of assays and tools to unravel the PD1 signaling pathways. As of today, we have several products and applications to detect and visualize PD1/PD-L1 interaction and signaling, read more here:
The latest news, not yet launched, is a PD1/PD-L1 profiling multiplex assay. To know more, come to our booth 1771!
Agata Wicher (CPO), Subham Basu (CBO), Lena Beckman (Marketing Manager), Doroteya Raykova (Application Scientist), Inge Cyrén (Area Manager North America), and Robert Gunnarsson (CEO).
We would love to meet you, please book a meeting with us here